Stifel initiates Immunome stock coverage with Hold rating at $24
Stifel initiated coverage on Immunome Inc. (IMNM) with a Hold rating and $24 price target, citing uncertainty around its lead drug and pipeline. The stock trades at $21.51, down 10% in a week but up 87% over a year. The FDA accepted Immunome's New Drug Application for varegacestat, with a target action date of April 28, 2027. The company also began a Phase 1 trial for IM-3050. H.C. Wainwright maintains a Buy rating and $40 target.
How this was made
The 30-second read
Why it matters
The FDA acceptance and strong Phase 3 data could accelerate the company's path to commercialization, improving liquidity and valuation.
Market read
Primary disclosure of regulatory acceptance and pivotal trial results makes this a high‑impact biotech news item.
What to watch
Potential competition in desmoid tumor treatments and the need for funding the upcoming radioligand program.
Background
Immunome is a clinical-stage biotech focusing on antibody‑drug conjugates and radioligand therapies.
Ticker impact
Stifel initiated coverage and the FDA accepted Immunome's New Drug Application for varegacestat, citing Phase 3 RINGSIDE trial data showing an 84% reduction in disease progression risk.
upward pressure as investors price in higher probability of eventual approval and commercial launch.
FDA acceptance and strong Phase 3 results are primary disclosures that materially improve the company's outlook.
Market effects
Boosts sentiment for the broader biotech/oncology pipeline sector as FDA engagement signals potential approvals.
Positive for US biotech investors and related exchange-traded funds.
Limited to investors tracking US biotech pipelines; no broader macro effect.
Counterpoint
The FDA may still request additional data, and the market could have priced in the acceptance already.
Key entities
- analystStifel
Initiated coverage with a Hold rating and $24 price target.
- regulatorFDA
Accepted the New Drug Application for varegacestat.
